Mar 17, 2021 11:05 JST

Source: Eisai

DZNE and Eisai Enter Into Research Collaboration Agreement Aiming for Novel Drug Discovery for Neurodegenerative Disorders

TOKYO, Mar 17, 2021 - (JCN Newswire) - Deutsches Zentrum fur Neurodegenerative Erkrankungen and Eisai Co., Ltd. today announced that both parties have entered into a research collaboration agreement aiming to create potential novel treatments for neurodegenerative disorders including Alzheimer's disease (AD) which modulate immune competence in neurons and glia cells.

DZNE is a world-leading interdisciplinary public research organization constituted with ten research sites in Germany that investigates methods for prevention, diagnosis and treatment against neurodegenerative diseases. The collaboration will incorporate DZNE's expertise in the fundamental and clinical research with Eisai's abundant experience in drug discovery for neurodegenerative diseases to accelerate development of novel drug candidates.

Prof. Pierluigi Nicotera, Chairman of the DZNE's Executive Board commented: "We are pleased to have formed this collaboration with Eisai, which has an outstanding track record and a company-wide commitment to providing innovative treatments in the neurodegenerative disorders field. We think that this collaboration will be able to accelerate creation of new treatments for neurodegenerative disorders, including those for Alzheimer's and Parkinson's. The DZNE will contribute knowledge and technical expertise in studying disease processes combined with our translational, patient-oriented approach that involves close interaction between fundamental and clinical research."

Dr. Teiji Kimura, Vice President, Chief Discovery Officer of the Eisai Neurology Business Group, commented: "Neurodegenerative diseases including AD comprise a disease area with high unmet medical needs. DZNE has many world-leading scientists in this field and we expect to create new disease-modifying therapies for those suffering from neurodegenerative disorders by conducting research for immune and metabolic incompetence in neurons and glia cells."

About Deutsches Zentrum fur Neurodegenerative Erkrankungen (DZNE)

The DZNE investigates all aspects of neurodegenerative diseases in order to develop novel approaches of prevention, treatment, and health care. It is comprised of ten sites across Germany and cooperates closely with universities, university hospitals, and other research institutions on a national and international level. The DZNE is a member of the Helmholtz Association of German Research Centers. For further information, please visit https://www.dzne.de/en/

About Eisai Co., Ltd.

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries. For further information on Eisai Co., Ltd., please visit https://www.eisai.com.

About Eisai Neurology External Innovation

Eisai's Global External Innovation team, as part of the Neurology Business Group, actively pursues novel approaches to medicines discovery through a growing network collaborations with external partners. Our partnership models are focused on the achievement of mutual goals that maximize sharing of complementary know-how, expertise and capabilities. Our ultimate goal is to advance new, ground-breaking science to identify and develop novel therapeutic concepts in neurodegeneration research that will accelerate innovative medicines discovery for the benefit of patients.

Source: Eisai
Sectors: BioTech, Healthcare & Pharm

Copyright ©2021 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai and National Cancer Center Commence Joint Research and Development Project
May 14 2021 16:48 JST
 
Eisai's Statement of Commitment for Carbon Neutrality by 2040
May 11 2021 09:00 JST
 
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Priority Review From FDA for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Applications
May 07 2021 10:08 JST
 
RESONA and Eisai Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia in Saitama Prefecture, Japan
April 28 2021 11:33 JST
 
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Uterine Body Cancer in Japan
April 23 2021 13:55 JST
 
Eisai: Gilead Sciences Submits New Drug Application in Japan for Filgotinib for the Treatment of Ulcerative Colitis with an Inadequate Response to Conventional Therapies
April 23 2021 12:02 JST
 
Notice Regarding Biogen's Disclosure About the Submission of Marketing Authorization Applications in Brazil, Canada, Australia, and Switzerland for Aducanumab for Alzheimer's Disease
April 23 2021 08:07 JST
 
Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease
April 20 2021 08:23 JST
 
Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting
April 14 2021 12:49 JST
 
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021
April 12 2021 12:16 JST
 
More Press release >>

Latest Press Release


More Latest Release >>